Breaking News

BiondVax Moves to New Flu Vaccine Mfg. Facility

State-of-the-art facility designed for annual capacity of 40 million doses in bulk with up to 20 million single dose syringes

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BiondVax Pharmaceuticals, developer of the M-001 universal influenza vaccine candidate, has relocated to a newly constructed mid-size commercial scale manufacturing facility in Jerusalem, Israel. “BiondVax’s new facility is custom-built for GMP manufacturing of our innovative flu vaccine candidate, which can be produced year-round and is designed to provide broad protection against influenza,” said Shimon Hassin, chief operating officer, BiondVax. “As BiondVax moves in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters